NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.<\/p>\n
Cantor Fitzgerald Global Healthcare Conference<\/p>\n
Chardan Genetic Medicines Conference<\/p>\n
Alliance for Regenerative Medicine: Cell & Gene Meeting on the Mesa<\/p>\n
About Sio Gene TherapiesSio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs\/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinsons disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit http:\/\/www.siogtx.com<\/a>.<\/p>\n Contacts:<\/p>\n Media Josephine Belluardo, Ph.D. LifeSci Communications(646) 751-4361jo@lifescicomms.cominfo<\/a>@siogtx.com<\/p>\n Investors and AnalystsParag V. MeswaniSio Gene Therapies Inc.Chief Commercial Officerinvestors@siogtx.com<\/a><\/p>\n <\/p>\n Link: NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. Continue reading
\nSio Gene Therapies to Participate in Upcoming Conferences - GlobeNewswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"